FDA grants Fast Track designation to prostate cancer treatment
Biopharmaceutical company Syncromune has had its lead-candidate for the treatment of metastatic castrate-resistant prostate cancer (mCRPC) granted Fast Track designation by the FDA. Syncromune’s SYNC-T SV-102 therapy is a personalised treatment that comprises of an in situ vaccine via partial oncolysis of a tumour followed by intratumoral infusion… Read More